Heart failure & cardiomyopathies
Rationale and Design of the FAIR-HF2-DZHK05 Trial: Ferric Carboxymaltose Assessment of Morbidity and Mortality in Patients with Iron Deficiency and Chronic Heart Failure
Study context
- Population
- Chronic heart failure (HF) with LVEF ≤45% and iron deficiency (serum ferritin <100 ng/ml or 100–299 ng/ml with transferrin saturation <20%)recruited
- Participants
- 1,105 participants
- Planned comparison
- Intravenous (IV) ferric carboxymaltose vs placebo
- Primary endpoint
- Three primary hypotheses: (i) time to first CV death or HF hospitalization; (ii) rate of total (first and recurrent) HF hospitalizations; (iii) time to first CV death or HF hospitalization in patients with transferrin saturation <20% at baseline
- Follow-up
- Estimated median over 2 years
Methodological detailsinvestigator-initiated, multicentre, double-blind, placebo-controlled
- Investigator-initiated
- Multicentre
- Double-blind
- Placebo-controlled
No results yet. This paper sets out the design of a trial; its results are to come.
Original publication
Rationale and Design of the FAIR-HF2-DZHK05 Trial: Ferric Carboxymaltose Assessment of Morbidity and Mortality in Patients with Iron Deficiency and Chronic Heart Failure. Eur J Heart Fail. Published 28 January 2025. doi:10.
Summarised from the published abstract; every number is checked against it